Primary Immune Deficiency (PID) - Drugs in Development: Strengthening the Immune System

Jul 11,2022 | Healthcare Services

Primary immunodeficiency is defined as a weakened immune system, allowing repeated infections and other health problems to occur more easily. Some of the early signs and symptoms include blood infections, pneumonia, bronchitis, sinus infections, ear infections, meningitis or skin infections, digestive problems, such as cramping, loss of appetite, nausea and diarrhoea.

The market report offered by Bharatbook provides comprehensive information on the therapeutics under development for Primary Immune Deficiency (PID) (Genetic Disorders) – Drugs in Development, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Preclinical and Discovery stages are 1, 12, 3, 10 and 4 respectively. Similarly, the Universities portfolio in Phase II, Phase I and Preclinical stages comprises 9, 1 and 3 molecules, respectively.

The study helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Furthermore it also features descriptive drug profiles which comprises of product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities, recognizes emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage, classify potential new clients or partners in the target demographic, develop tactical initiatives by understanding the focus areas of leading companies. Also plans mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.

To get more insights on the aforementioned market, please visit Primary Immune Deficiency (PID) (Genetic Disorders) – Drugs in Development.